Pembrolizumab benefit confirmed for cisplatin-ineligible advanced UC patients | Peter O’Donnell

Peter O’Donnell gives an update on the KEYNOTE-052 trial findings for first-line pembrolizumab in cisplatin-ineligible patients with advanced urothelial carcinoma (2:36).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany